Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals

US · 2026-10-02

1. Step 1 · The triggerNovartis licenses Abogen's drug assets for up to $7.8bn, transferring capital and pipeline rights to Abogen.
2. Step 2 · Knock-onWestern Big Pharma, facing patent expirations, intensifies competition for China-origin drug assets, raising valuations and deal flow for Chinese biotechs.
3. Step 3 · Reaches youUS SMEs in pharma supply, clinical services, and R&D face higher input costs and tighter competition as global licensing activity accelerates.

The trigger is reported by the source below. The steps that follow are Branch²’s traced reasoning — how the shock could reach a business like yours, not a prediction.

Source: CNBC

This is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.